(Corrects to say second bidder will propose merger of equals in second paragraph)
Celgene Corp. (CELG:US) is one of two companies other than GlaxoSmithKline Plc (GSK) weighing a bid for Human Genome Sciences Inc., Reuters says, citing a source familiar with the situation that it didn’t identify.
A second unidentified bidder would propose a merger of equals, Reuters said yesterday. Glaxo has offered to buy Human Genome for $13 a share, and the U.S. biotechnology company has set a July 16 deadline for competing bids.
To contact the reporter on this story: Makiko Kitamura in London at email@example.com
To contact the editor responsible for this story: Dick Schumacher at firstname.lastname@example.org